Top

Published in:

01-12-2010 | Original Article

Hepatic metastases from breast cancer

Authors: Arianna Rubino, Roberto Doci, Jean Claude Foteuh, Emanuela Morenghi, Susanna Fissi, Casimiro Giorgetta, Islam Abumalouh, Luca Di Tommaso, Leandro Gennari

Published in: Updates in Surgery | Issue 3-4/2010

Abstract

The prognosis of patients with hepatic metastasis from breast cancer treated with systemic or regional chemotherapy is disappointing. When technically feasible, liver resection offers the best results. Eighteen patients out of 22 submitted to laparotomy underwent radical liver resection. Median follow-up from liver resection was 36 months. The median time interval between breast cancer diagnosis and disease recurrence was 35 months. Median disease-free survival and overall survival from liver resection were 66 and 74 months, respectively. Median survival time from breast cancer surgery was 88.5 months. Surgical treatment of liver metastases should be carried out on young and older patients alike when site of metastases is the liver alone. Neoadjuvant treatment and preoperative diagnostic laparoscopy should be planned in future experience.

Wingo PA, Tong T, Bolden S (1995) Cancer statistics. CA Cancer J Clin 45(1):8–30CrossRefPubMed

Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41:1170–1178CrossRefPubMed

Haagensen CD (1977) Treatment of curable carcinoma of the breast. J Radiol Oncol Biol Phys 2:975–980CrossRef

Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, Robertson JF, Evans AJ (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89:284–290CrossRefPubMed

Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Quevas MA, Alvarez LA (1990) Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Am J Clin Oncol 13:294–298CrossRefPubMed

Baur M, Schlappack O, Havelec L, Wrba F, Dittrich C (2001) Prognostic significance of liver metastases as first site of generalisation in patients with breast cancer—a retrospective analysis. Acta Med Austriaca 28:135–140CrossRefPubMed

Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271–278CrossRefPubMed

Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56(1):67–78CrossRefPubMed

Yoshimoto M, Tada T, Saito M, Takahashi K, Uchida Y, Kasumi F (2000) Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Rest Treat 59:177–184CrossRef

10.

Elias D, Maisonnette F, Druet-Cabanac M, Ouellet JF, Guinebretiere JM, Spielmann M, Delaloge S (2003) An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 185:158–164CrossRefPubMed

11.

Sakamoto Y, Yamamoto J, Yoshimoto M, Kasumi F, Kosuge T, Kokudo N, Makuuchi M (2005) Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg 29:524–527CrossRefPubMed

12.

Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–908CrossRefPubMed

13.

Pocard M, Pouillard P, Asselain B, Salmon R (2000) Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol 26:155–159CrossRefPubMed

14.

Thelen A, Benckert C, Jonas S, Lopez-Hänninen E, Sehouli J, Neumann U, Rudolph B, Neuhaus P (2008) Liver resection for metastases from breast cancer. J Surg Oncol 97:25–29CrossRefPubMed

15.

Lubrano J, Roman H, Tarrab S, Resch B, Marpeau L, Scotté M (2008) Liver resection for breast cancer metastasis: does it improve survival? Surg Today 38:293–299CrossRefPubMed

16.

Neri A, Marrelli D, Pedrazzani C, Caruso S, De Stefano A, Mariani F, Megha T, De Marco G, Corso G, Pinto E, Rovello F (2008) Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. EJSO 34:1299–1303PubMed

17.

Konecny GE, Thomssen C, Lück HJ, Unth M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ (2004) Her-2/neu gene amplification and response to paclitaxel in patients with metastastic breast cancer. J Natl Cancer Inst 96:1141–1151CrossRefPubMed

18.

Gennari L, Doci R, Bozzetti F, Veronesi U (1982) Proposal for a clinical classification of liver metastases. Tumori 68:443–449PubMed

19.

Zhou P, Recht A (2004) Young age and outcome for women with early stage invasive breast carcinoma. Cancer 101(6):1264–1274CrossRefPubMed

20.

Matthews R, McNeese M, Montague E, Oswald MJ (1988) Prognostic implications of age in breast cancer patients treated with tumorectomy and irradiation or mastectomy. Int J Radiat Oncol Biol Phys 14:659–663CrossRefPubMed

21.

Eichbaum MH, Kaltwasser M, Bruckner T, de Rossi TM, Schneeweiss A, Sohn C (2006) Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat 96:53–62CrossRefPubMed

22.

Martinez SR, Young SE, Giuliano AE, Bilchik AJ (2006) The utility of estrogen receptor, progesterone receptor and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. Am J Surg 191:281–283CrossRefPubMed

23.

Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A (2009) HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501–507CrossRefPubMed

24.

Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N (2008) Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res 14:6602–6609CrossRefPubMed

25.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P (2005) Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11:278–280CrossRefPubMed

26.

Brown M, Tsodikov A, Bauer K, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer. Cancer 112(4):737–747CrossRefPubMed

27.

Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 8:347–353CrossRefPubMed

28.

de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R (2008) R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 248(4):626–637PubMed

29.

Yang SH, Yang KH, Li YP, Zhang YC, He XD, Song AL, Tian JH, Jiang L, Bai ZG, He LF, Liu YL, Ma B (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19(6):1039–1044CrossRefPubMed

30.

Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420–1430CrossRefPubMed

Title: Hepatic metastases from breast cancer
Authors: Arianna Rubino
Roberto Doci
Jean Claude Foteuh
Emanuela Morenghi
Susanna Fissi
Casimiro Giorgetta
Islam Abumalouh
Luca Di Tommaso
Leandro Gennari
Publication date: 01-12-2010
Publisher: Springer Milan
Published in: Updates in Surgery / Issue 3-4/2010
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-010-0026-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hepatic metastases from breast cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2010

Plasma cholesterol level after hepatopancreatobiliary surgery provides information on the postoperative clinical course

First experience for the laparoscopic treatment of parastomal hernia with the use of Parietex composite mesh

Intravascular lipoma from iliofemoral tract

Hepatobiliary cystoadenoma: a wolf in sheep’s clothing

Role of portal vein embolization in liver surgery: single centre experience in sixty-two patients

Early results and complications of colorectal laparoscopic surgery and analysis of risk factors in 492 operated cases